Articular Damage in Patients With Juvenile Idiopathic Arthritis After Transition to Adult Care
Key facts
- Who runs it
- IRCCS Burlo Garofolo
- Where
- Italy3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 1 Apr 2025
- Planned end
- 31 Dec 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Methotrexate
- Biological Drug
- Record updated
- 26 March 2025
Who can take part
- Age
- 16 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients aged between 16 to 25 years who received a diagnosis of JIA in pediatric age according to International League of Associations for Rheumatology criteria (2001) and who have begun the process of transition to adult care
- Young adults undergoing healthcare transition process from the the pediatric to adult rheumatology since 2016
- Patients with radiological evidence of joint plates closure
- X-ray images of hands, hips, and knees available
Who cannot take part
- Patients cared at the adult rheumatology clinic who received a diagnosis of arthritis in the adult age
- Patients with other orthopedic conditions or affected by other diseases leading to osteoporosis or skeletal deformities
- Patients affected by other rheumatological conditions who underwent healthcare transition process from the the pediatric to adult rheumatology center
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 16 and 25 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Juvenile idiopathic arthritis (JIA) is the most common childhood chronic rheumatic disease, encompassing all forms of arthritis that persist for more than 6 weeks, with onset before age 16, after exclusion of other causes of arthritis. It is a heterogeneous disease, whose complexity is only partially encompassed by the actual classification criteria and it is characterized by prolonged synovial inflammation that can lead to joint destruction.
Read full original descriptionShow less
Whilst the assessment of structural joint damage is part of the routinary evaluation of disease severity and progression in patients with rheumatoid arthritis (RA), to the extent that it is considered a key end-point outcome in treatment efficacy studies, this is not the same for JIA. Some recommendations have been elaborated based on expert opinion, but only recently they have been translated into clinical practice. Such a discrepancy in approaching chronic arthritis has been for many years due to the lack of articular damage radiographic scoring system validated for pediatric age. Actually, joint space narrowing, bone erosions and demineralization, which is typical of adult articular damage, are not the same changes observed in pediatric population where early growth plate closure, epiphyseal deformity and growth asymmetries can be the major signs.
The transition process from the pediatric to the adult health care team is a critical moment in the clinical history of patients with JIA, often hampered by the absence of specific criteria for the assessment of disease activity, the lack of specific treatment recommendations for JIA adult patients, the poor adolescent-specific training for adult rheumatologists, and the lack of communication between pediatric and adult centers. Adult patients with JIA have their own specific identity and should not be inappropriately re-categorized as having RA, ankylosing spondylitis or another condition once transitioned to the adult rheumatologist.
The aim of this study is to quantify the articular damage of adult patient with JIA after closure of growth plates. This represent a sort of starting burden carried by the patients who receive transition to the adult rheumatologist care and which should be minimized in order to reduce long-term complications. Furthermore, the study aims to analyze possible correlations between the presence of articular damage, therapies taken in pediatric age, and characteristics of JIA at the onset and during the clinical course of the disease
The 2 groups in the trial
- Methotrexate group
Patients who underwent transition from pediatric to adult rheumatology care who spent most of their disease time on methotrexate therapy
Treatment: Methotrexate
- Biologic therapy group
Patients who underwent transition from pediatric to adult rheumatology care who spent most of their disease time on biologic therapy
Treatment: Biological Drug
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Articular Damage in Patients With Juvenile Idiopathic Arthritis (JIA) After Transition to Adult Care and Correlation With Disease Characteristics and Treatments.
- Criteria questions
- Built from NCT06895278, who can take part
- Record updated
- 26 March 2025